A Prospective, Non-interventional Study of the Use of Dolutegravir as Part of Combination Antiretroviral Therapy in Routine Daily Practice in Germany (DOL-ART)
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 03 Jun 2017
At a glance
- Drugs Dolutegravir (Primary)
- Indications HIV infections
- Focus Therapeutic Use
- Acronyms DOL-ART
- Sponsors ViiV Healthcare
- 16 Aug 2016 Planned End Date changed from 1 Jun 2017 to 1 May 2017.
- 16 Aug 2016 Planned primary completion date changed from 1 Jun 2017 to 1 May 2017.
- 01 Feb 2015 Planned End Date changed from 1 Dec 2017 to 1 Jun 2017 as reported by ClinicalTrials.gov record.